A previous study reported no significant correlation between the GR status and the clinical outcome in ESCC patients [7]; however, in the current study, we comprehensively evaluated GR immunoreactivity using the H-score. This evidence concerns the gene NR3C1 and esophageal squamous cell carcinoma.